Anuh Pharma Ltd Q4 FY22 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- The company targets sales of Rs. 600 crores for FY 2023, showing optimism about demand resumption despite currently falling short.
- Plans to introduce five new API products in FY23: Allopurinol, Acebrophylline, Citicoline, Theophylline, and Caffeine, to build growth foundation.
- Focus on increasing market share of existing products and geographic expansion in Vietnam, Japan, and South Korea.
- Approval filings (CEP for Gliclazide, Azithromycin and WHO PQ for Isoniazide) expected to open European market and institutional business, potentially adding Rs. 50 crore in sales within two years post-approval.
- Manufacturing capacity utilization is about 60%, with potential to add 300 tons capacity by machinery addition.
- R&D and compliance (environment, safety, GMP) are key pillars supporting sustainable growth.
- Expect demand improvement post-pandemic and seasonally from June to October (monsoon period).
See what Anuh Pharma Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no mention of any current or planned fundraising through debt or equity in the transcript.
- The company has not indicated plans for new equity issuance or debt raising in the discussion.
- Focus appears to be on operational growth, increasing market share, and capital expenditure mainly related to capacity expansion (Rs. 40 to 50 lakhs in FY23) rather than raising external funds.
- The conversation and queries were more centered around shareholding patterns, buyback suggestions, and realistic growth expectations rather than new fundraising.
- No statements about issuing new shares or raising debts were made during the call or in management's closing remarks.
See what Anuh Pharma Ltd management said on order book — free account, 30 seconds.
Capex plans
Yes- The company plans capital expenditure of approximately Rs. 40 to 50 lakhs in FY23 to bring versatility in production capabilities by adding machinery.
- They have previously made CAPEX of Rs. 70 crores in 2019, which expanded manufacturing capacity to 1500 tons; currently utilizing about 60% of this capacity.
- Company focuses on R&D and plans to introduce five new API products in FY23 (Allopurinol, Acebrophylline, Citicoline, Theophylline, and Caffeine) to build a foundation for future growth.
- There is no specific mention of strategic investments, but the company aims to increase market presence geographically (Vietnam, Japan, South Korea) and expand sales in the European market via CEP and WHO PQ filings.
Track Anuh Pharma Ltd — get its next earnings analysis in your feed
How does Anuh Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Anuh Pharma Ltd rank in Pharmaceuticals & Biotechnology?
Compare Anuh Pharma Ltd against every Pharmaceuticals & Biotechnology company (Q4 FY22) on revenue, margins and earnings-call signals.
Continue your research
What Anuh Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
- Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
- RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
- FDC Ltd (Q3 FY23)
Q3FY23 Revenue from operations: ₹407 crores, up 19% YoY from ₹341 crores in Q3FY22 (Page 13). Key concall takeaways from FDC Ltd's Q3 FY23 earnings call — and…